Berlin/Germany December 14, 2020 -The drug delivery specialist Alrise Biosystems GmbH has entered into an Asset Purchase and Exclusive License Agreement with Ferring International Center S.A. for the development and commercialisation of products manufactured with Alrise's ImSus® platform technology.
Alrise and Ferring have been working together since 2017 on the development of an injectable, controlled-release formulation of a peptide therapeutic. Based on the successful partnership Ferring has now exercised its option to enter into a definite agreement to further leverage and get exclusive access to Alrise’s process knowhow and intellectual property rights. The parties have committed not to disclose the contractual terms and conditions as well as details of the on-going product development.
“We are pleased that we were able to continue and strengthen our successful collaboration with Ferring”, stated Dr. Heiko Seemann, Alrise’s Managing Director. “This agreement paves the way to making the first product utilising our ImSus® technology platform available to patients.”
“On this occasion we would like to express our special thanks to our investors IBB Ventures and Creathor Ventures for their long-standing trust and support”, Dr. Volker Rindler, Alrise’s Managing Director, added. “Our thanks also go to our consultants from tytonis b.v. and Bay Pharma GmbH for their help in various business development matters.”
“We are very grateful to Alrise's management Dr. Rindler and Dr. Seemann for developing products based on novel pharmaceutical dosage forms that will improve medications for patients worldwide with Ferring’s acquisition.” comments Karlheinz Schmelig, Managing Partner of Creathor Ventures.
About Alrise
Alrise Biosystems GmbH is a drug delivery company located in the Biotech Park Berlin-Buch and is managed by Dr. Heiko Seemann und Dr. Volker Rindler. Through application of its ImSus® technology platform Alrise develops drug-loaded micro particle formulations, which are used for injectable, controlled-release depot products. The company has been financed primarily through venture capital investments from the VC companies Creathor Venture and IBB Ventures.
About Creathor Ventures
Creathor Ventures invests in technology-oriented companies that drive the automation of industry and business, and the personalization and digitalization of healthcare. From its locations in Germany and Switzerland, the team currently supports over 30 tech and healthcare companies. Over the past 30 years, the management team has financed over 200 companies as lead or co-lead investors. More than 20 companies have been listed on international stock exchanges. Creathor Ventures currently manages a fund volume of over 230 million euros. Further information can be found at: www.creathor.com
For further informations please contact:
Karlheinz Schmelig
Managing Partner
Phone: +49 6172 139720
Email: karlheinz.schmelig@creathor.com